Editorial

Our failure to advance new treatments for glioma to market

Restricted access

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Information

Contributor Notes

Please include this information when citing this paper: published online May 13, 2011; DOI: 10.3171/2010.11.JNS101436.

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1

    Ardon HDe Vleeschouwer SVan Calenbergh FClaes LKramm CMRutkowski S: Adjuvant dendritic cellbased tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer 54:5195252010

    • Search Google Scholar
    • Export Citation
  • 2

    Cheever MAAllison JPFerris ASFinn OJHastings BMHecht TT: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:532353372009

    • Search Google Scholar
    • Export Citation
  • 3

    De Vleeschouwer SFieuws SRutkowski SVan Calenbergh FVan Loon JGoffin J: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:309831042008

    • Search Google Scholar
    • Export Citation
  • 4

    Ditts DMSandler ABBaker MCheng SKGeorge SLKaras KS: Processes to activate Phase III clinical trials in a cooperative oncology group: the case of Cancer and Leukemia Group B. J Clin Oncol 24:455345572006

    • Search Google Scholar
    • Export Citation
  • 5

    Herper M: The world's most expensive drugs. Forbes February222010. (http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases.html) [Accessed April 15 2011]

    • Search Google Scholar
    • Export Citation
  • 6

    Hodi FSO'Day SJMcDermott DFWeber RWSosman JAHaanen JB: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:7117232010

    • Search Google Scholar
    • Export Citation
  • 7

    Liau LMPrins RMKiertscher SMOdesa SKKremen TJGiovannone AJ: Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:551555252005

    • Search Google Scholar
    • Export Citation
  • 8

    Muragaki YMaruyama TIseki HTanaka MShinohara CTakakura K: Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg [epub ahead of print May 13 2011. DOI: 10.3171/2011.4.JNS10377]

    • Search Google Scholar
    • Export Citation
  • 9

    Okada HLieberman FSEdington HDWitham TFWargo MJCai Q: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64:13202003

    • Search Google Scholar
    • Export Citation
  • 10

    Okada HLieberman FSWalter KALunsford LDKondziolka DSBejjani GK: Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 5:672007

    • Search Google Scholar
    • Export Citation
  • 11

    Okada HPollack IFLotze MTLunsford LDKondziolka DLieberman F: Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 11:6376532000

    • Search Google Scholar
    • Export Citation
  • 12

    Plautz GEMiller DWBarnett GHStevens GHMaffett SKim J: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6:220922182000

    • Search Google Scholar
    • Export Citation
  • 13

    Sampson JHAldape KDArcher GECoan ADesjardins AFriedman AH: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:3243332011

    • Search Google Scholar
    • Export Citation
  • 14

    Sampson JHArcher GEMitchell DAHeimberger ABHerndon JE IILally-Goss D: An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8:277327792009

    • Search Google Scholar
    • Export Citation
  • 15

    Sampson JHHeimberger ABArcher GEAldape KDFriedman AHFriedman HS: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:472247292010

    • Search Google Scholar
    • Export Citation
  • 16

    Sloan AEDansey RZamorano LBarger GHamm CDiaz F: Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colonystimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus 9:6e92000

    • Search Google Scholar
    • Export Citation
  • 17

    Small EJSchellhammer PFHigano CSRedfern CHNemunaitis JJValone FH: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24:308930942006

    • Search Google Scholar
    • Export Citation
  • 18

    Smith JSCha SMayo MCMcDermott MWParsa ATChang SM: Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg 103:4284382005

    • Search Google Scholar
    • Export Citation
  • 19

    Tang JFlomenberg PHarshyne LKenyon LAndrews DW: Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells. Clin Cancer Res 11:529252992005

    • Search Google Scholar
    • Export Citation
  • 20

    Ueda RLow KLZhu XFujita MSasaki KWhiteside TL: Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med 5:682007

    • Search Google Scholar
    • Export Citation
  • 21

    Van Gool SMaes WArdon HVerschuere TVan Cauter SDe Vleeschouwer S: Dendritic cell therapy of high-grade gliomas. Brain Pathol 19:6947122009

    • Search Google Scholar
    • Export Citation
  • 22

    Wakimoto HAbe JTsunoda RAoyagi MHirakawa KHamada H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56:182818331996

    • Search Google Scholar
    • Export Citation
  • 23

    Waterhouse PPenninger JMTimms EWakeham AShahinian ALee KP: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:9859881995

    • Search Google Scholar
    • Export Citation
  • 24

    Wheeler CJBlack KLLiu GMazer MZhang XXPepkowitz S: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:595559642008

    • Search Google Scholar
    • Export Citation
  • 25

    Wheeler CJDas ALiu GYu JSBlack KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:531653262004

    • Search Google Scholar
    • Export Citation
  • 26

    Wu AHXiao JAnker LHall WAGregerson DSCavenee WK: Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76:23302006

    • Search Google Scholar
    • Export Citation
  • 27

    Yamanaka RAbe TYajima NTsuchiya NHomma JKobayashi T: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:117211792003

    • Search Google Scholar
    • Export Citation
  • 28

    Yang IHan SParsa AT: Heat-shock protein vaccines as active immunotherapy against human gliomas. Expert Rev Anticancer Ther 9:157715822009

    • Search Google Scholar
    • Export Citation
  • 29

    Yang ITihan THan SJWrensch MRWiencke JSughrue ME: CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17:138113852010

    • Search Google Scholar
    • Export Citation
  • 30

    Yu JSLiu GYing HYong WHBlack KLWheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:497349792004

    • Search Google Scholar
    • Export Citation
  • 31

    Yu JSWheeler CJZeltzer PMYing HFinger DNLee PK: Vaccination of malignant glioma patients with peptidepulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61:8428472001

    • Search Google Scholar
    • Export Citation
  • 1

    Butowski NLamborn KRLee BLPrados MDCloughesy TDeAngelis LM: A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 91:1831892009

    • Search Google Scholar
    • Export Citation
  • 2

    Okada HKalinski PUeda RHoji AKohanbash GDonegan TE: Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:3303362010

    • Search Google Scholar
    • Export Citation
  • 3

    Sampson JHHeimberger ABArcher GEAldape KDFriedman AHFriedman HS: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:472247292010

    • Search Google Scholar
    • Export Citation
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 180 178 70
Full Text Views 86 45 2
PDF Downloads 34 28 0
EPUB Downloads 0 0 0
PubMed
Google Scholar